Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study groupAntonio Bertolotto, Simona Malucchi, Maria di Ioia et al.|Neurological Sciences|2013Cited by 37
Erratum to: Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study groupAntonio Bertolotto, Simona Malucchi, Marco Capobianco et al.|Neurological Sciences|2014Cited by 2
Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumabAlessandra Sottini, Luisa Imberti, Virginia Quaresima et al.|Journal of Neuroimmunology|2023Cited by 1